

## Busulfan

S

### **Sinusoidal obstruction syndrome with thrombotic microangiopathy: case report**

A 1.5-year-old boy developed sinusoidal obstruction syndrome with thrombotic microangiopathy following treatment with busulfan for Wiskott-Aldrich Syndrome [WAS; *route, dosage, duration of treatment to reaction onset and outcome not stated*].

The boy, who had been diagnosed with WAS at the age of 3 months, started receiving busulfan (weight and area under the curve (AUC)- targeted, target AUC  $48000 \pm 10\%$  ng/mL×h) along with other drugs followed by gene therapy (GT) at the age of 1 years. Subsequently, he developed sinusoidal obstruction syndrome suspected thrombotic microangiopathy possibly associated with an unexpected high busulfan exposure (AUC 80 988 ng/mL×h) and then resolved without sequelae. In March 2020 (5 months after GT), he tested positive for SARS-CoV-2 infection. He was then treated with off-label hydroxychloroquine 2.5 mg/kg twice a day and lopinavir/ritonavir 12 mg/kg twice daily. Forty days later, he tested negative for SARS-CoV-2 infection.

Cenciarelli S, et al. Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report. *Frontiers in Immunology* 11: 24 Nov 2020.  
Available from: URL: <http://doi.org/10.3389/fimmu.2020.603428>

803593199